In July 2025, Novartis Pharmaceuticals conducted a Phase III multi-center, single dose (1.2 x 1014 vector genomes), ...

More Hong Kong patients suffering from spinal muscular atrophy (SMA) will be able to enjoy a government subsidy to control ...

As treatment for spinal muscular atrophy (SMA) has drastically improved over the last decade, so too have survival rates and the number of people with SMA living well into adulthood. | A new education ...

It will grow to $9.02 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- Save ...

The court said Switzerland’s refusal to pay for Spinraza for a quadriplegic patient with spinal muscular atrophy did not ...

Spinal muscular atrophy (SMA) is an autosomal recessive genetic disease that causes progressive degeneration of motor neurons, affecting approximately 1 in 10,000 births.

Remini shared an emotional tribute to the 21-year-old she met while filming the "King of Queens" sitcom: "I want people to ...

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show ...

For people like 16-year-old Vivienne Liedtke, who was born with the physical disability spinal muscular atrophy, finding a ...

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim findings from a Phase I study.